An overview on the interplay between nutraceuticals and gut microbiota

View article


The “nutraceuticals” terminology was firstly introduced by Dr. Stephen L. DeFelice in 1989 and represents the link between nutrition and the pharmaceutical field. After 1994, when the place of dietary supplements in maintaining people’s health was established, the term “nutraceuticals” was extended to include this category, too. Vitamins, minerals, herbs, amino acids and others belong to dietary supplements class, hence to the nutraceutical class (Gupta et al., 2010). Nutraceuticals are products isolated or purified from foods. They are sold in dosage form and are not usually associated with food, which play an important role in modifying and/or maintaining physiological functions or offering protection against chronic diseases (Das et al., 2012; Romano et al., 2012).

Nutraceuticals can be classified in potential nutraceuticals and established nutraceuticals. The majority of nutraceuticals belong to the first category, as many preclinical and clinical studies are still necessary in order to prove their beneficial effects. Only a few classes belong to the second category, e.g., probiotics, prebiotics, omega 3 fatty acids and antioxidants. For these classes, many studies which confirm beneficial effects in certain conditions are already available (Pandey, Verma & Saraf, 2010; Alisi et al., 2014; Riva et al., 2017).

Furthermore, there are two other classifications of nutraceuticals: based on chemical constituents (Nutrients, Dietary Supplements, Herbs) or Traditional/Non-traditional nutraceuticals (Gupta et al., 2010).

We cannot refer to nutraceuticals without connecting them with the human’s microbiota which represents the total microorganisms which colonize the host at different levels: gastrointestinal tract, respiratory tract, skin, vagina and so on. The number of these microorganisms is estimated to 1014, representing a number 10 times higher than that of human cells (Thursby & Juge, 2017).

The most developed one is the gastrointestinal microbiota with an unequal distribution along the digestive tract. There are few bacteria in the stomach and first part of the small intestine, but the concentration increases reaching a maximum in the colon (Montalto et al., 2009).

Adult healthy subjects have six bacterial phyla dominating the gut microbiota: Firmicutes and Bacteroidetes (90%), Proteobacteria, Actinobacteria, Fusobacteria and Verrucomicrobia (Woting & Blaut, 2016).

Firmicutes and Bacteroidetes represent the main bacteria phyla, whose proportion remains the same during lifetime for a person (older than 3 years old) and their family members (Tang & Hazen, 2014).

The aim of this review is to summarize the current knowledge about the nutraceuticals interaction with gut microbiota and how we could use this class of supplement in different pathologies related to dysbiosis and leaky gut condition. Furthermore, there will be listed a number of nutraceuticals scientifically proved to have beneficial effect on healing the gut barrier and promoting the eubiosis.

Survey Methodology

We performed an electronic literature search in the PubMed database and we included relevant articles published after 2000. In our search we used the following terms: “nutraceuticals”, “food supplements”, “health benefits” in combination with “gut microbiota” or “gastrointestinal bacteria”. In this review, we included evidences from various types of studies: observational and experimental studies, both in vitro and in vivo researches, including randomized controlled ones. Overall selected papers were used for the purposes of this review.

The importance of gut microbiota

A few species of the colon’s bacteria have an important role in the bacterial degradation of amino-acids and formation of short-chain fatty acids (SCFAs)—rich sources of energy for the host and metabolic signaling (Jandhyala et al., 2015; Woting & Blaut, 2016). Bacteroidetes produce acetate and propionate, while Firmicutes families (Lachnospiraceae, Ruminococcaceae) mainly produce butyrate as primary metabolic end products (Den Besten et al., 2013; Louis & Flint, 2017). Butyrate is the most important component of energetic metabolism in the colonocytes, while acetate and propionate are used as substrates for lipogenesis, gluconeogenesis and protein synthesis (Schwiertz et al., 2010; Tremaroli & Bäckhed, 2012). Acetate, propionate and butyrate play an important role in the regulation of hepatic lipids and glucose homeostasis, including the effect of peroxisome proliferator-activated receptors (PPAR) on gluconeogenesis and lipogenesis (Morrison & Preston, 2016).

Moreover, the gut bacteria metabolize tryptophan to active substances. For example, E. coli produces indoles which play an important role as signaling molecules with mainly physiological roles (motility, biofilm formation and antibiotic resistance) (Li & Young, 2013; Levy, Blacher & Elinav, 2017).

The SCFAs inhibit histone deacetylase (HDAC) and ligands for certain G-protein coupled receptors (GPRs). The result of broad expression inhibition of both (HDAC and GPR) explains the physiological roles of SCFAs: regulation of blood pressure, kidney function, nervous system and protection against colon cancer (Alex et al., 2013; Pluznick, 2014; Steinmeyer et al., 2015; Joseph et al., 2017).

SCFAs are also involved in the activation of free fatty acid receptors—FFAR2 and FFAR3—G protein-coupled receptors that function as signaling molecules in many physiological processes. These receptors can be found in many cells: adipocytes, pancreatic islet, incretin-releasing enteroendocrine cells (K cells—gastric inhibitory polypeptide release, I cells—cholecystokinin release, L cells—glucagon-like peptide-1 and peptide YY release). Moreover, FFAR2 are expressed in neutrophils and small intestine dendritic cells (Hara et al., 2011; Alvarez-Curto & Milligan, 2016).

Gut microbiota and associated health problems.

Figure 1: Gut microbiota and associated health problems.

Table 1:
The link between several diseases and changes of microbiota.
Disease Changes in microbiota’s diversity and composition Consequences Reference
Inflammatory bowel disease Less bacterial diversity ↓ the number of Bacteroides and Firmicutes decreasing the concentration of butyrate Lucas López et al. (2017)
Irritable bowel syndrome—diarrhea EnterobacteriaceaeFaecalibacterium prausnitzii not known Dupont (2014)
Constipation Firmicutes(Lachnospiraceae and Ruminococcaceae)Bacteroidetes (Prevotella) increasing the production of butyrate Zhu et al. (2014)
Obesity Changes in the ratio of Bacteroidetes/Firmicutes↓ the abundance Akkermansia muciniphila↑ the abundance Campylobacter, Shigella, Prevotella decreasing the production of butyrate Festi et al. (2014)Tremaroli & Bäckhed (2012)
Diabetes tip 2 Bifidobacterium spp significant association of Parabacteroides with diabetic patients not known Wu et al. (2010)
FirmicutesBacteroidetes, Proteobacteria it is possible to determine endotoxemia → oxidative stress → IL1, IL6, TNF α Marlene (2013)
Diabetes tip 1 Lactobacillus, Bifidobacterium, Blautia coccoides–Eubacterium rectale, Prevotella decreasing the production of butyrate decreasing the synthesis of mucin increasing the intestinal permeability Murri et al. (2013)
Clostidium clusters IV and XIV (species that produce butyrate) decreasing the production of butyrate De Goffau et al. (2014)
Dyslipidemia Lactobacillus decreasing enzymatic deconjugation of bile acids → increasing the level of cholesterol Kumar et al. (2012), Ramakrishna (2013)
Nonalcoholic steatohepatitis FirmicutesFaecalibacterium and Anaerosporobacter (order Clostridiales)Parabacteroides and Allisonella (order Aeromonadales) increase in luminal gut ethanol production metabolism of dietary choline release of lipopolysaccharides increasing small intestinal bacterial overgrowth increasing endotoxemia increasing lipopolysaccharide →↑ insulin resistance and ↑ TNF alpha Compare et al. (2012), Wong et al. (2013) and Machado & Cortez-Pinto (2012)
Acute coronary syndromes not know trimethylamine is formed by gut microbiota from nutrients which contain l-carnitine, choline, phosphatidylcholine followed by the formation of trimethylamine N-oxide (TMAO) by hepatic enzymes increasing the plasmatic level of TMAO–increasing the risk of myocardial infarction and stroke Trøseid (2017)
Autistic spectrum disorders Clostridium histolyticum (Clostridium clusters I and II)Bacteroidetes, DesulfovibrioFirmicutes increasing the production of neurotoxins Parracho et al. (2005), De Angelis et al. (2013)
Allergy Lactobacillus, Enterococcus increasing of allergic sensitization Kirjavainen et al. (2002)
low diversity of microbiota ↑BacteroidalesClostridiales not know Hua et al. (2016)
DOI: 10.7717/peerj.4465/table-1

Many studies demonstrated that SCFAs play important roles in the prevention and treatment of the metabolic syndrome, gastro-intestinal diseases (Crohn’s disease, ulcerative colitis or antibiotic-associated diarrhea) and even in certain types of cancer (Den Besten et al., 2013; Kim, Park & Kim, 2014; Weitkunat et al., 2017; Zeng et al., 2017). It is well-known that exposure to various environmental factors (diet, drugs, toxins and pathogens) can cause the alterations of the gut microbiota, known as dysbiosis, with a direct implication in the production of SCFAs. Many studies were dedicated to microbiome and gut barrier. The interaction between microbiota and host immune system proved to be the key element in a new understanding the pathogenesis of a large spectrum of diseases like GI tract disease (inflammatory bowel disease IBD, irritable bowel syndrome IBS, nonalcoholic steatohepatitis NASH, cirrhosis, chronic pancreatitis, gastro-esophagean reflux disease GERD) or extra-intestinal diseases (allergy, asthma, metabolic syndrome, cardiovascular diseases,neurodegenerative disease, psychiatric disease and autoimmune disease) (Fig. 1) (Tang & Hazen, 2014; Carding et al., 2015). However, the microbiota changes over time and there are many variations in diversity and abundance of bacteria between children and the elderly (Buford, 2017; Elderman et al., 2017). The link between several diseases and changes of the microbiota is summarized in Table 1.

According to the latest surveys, there are many reported dietary supplements used to restore the equilibrium of gut microbiota (Fig. 2).

Probiotics have been defined by WHO as “live micro-organisms which, when administered in adequate amounts, confer a health benefit on the host” (Walker & Lawley, 2013).

The probiotics can restore the normal composition of microbiota (abundance and diversity) by producing SCFAs. There are many studies which demonstrated that Lactobacillus species (L. casei, rhamnosusand acidophilus) can prevent or can reduce the severity of antibiotic associated diarrhea (AAD) (Huazano-Garcia, Hakdong & Lopez, 2017; Park et al., 2017), while species belonging to Lactobacillus, Bifidobacterium or Escherichia coli Nissle 1917 can prevent or treat gastro-intestinal diseases or metabolic disorders (Woting & Blaut, 2016).

Johnston and coworkers performed a meta-analysis study in order to determine whether concomitant administration of probiotics and antibiotics prevents or diminishes the AAD in children. Twenty-three studies were included in this meta-analysis (Johnston et al., 2011). The probiotic treatment was constituted especially of Bacillus sp, Bifidobacterium sp, Clostridium butyricum, Lactobacilli spp., Lactococcus spp., Leuconostoc cremoris, Saccharomyces spp., or Streptococcus spp., alone or in combination. The results demonstrated a beneficial effect of probiotics on AAD incidence (probiotic 8% vs. control 19%) (Johnston et al., 2011).

Akkermansia muciniphila, discovered in 2004 by Derrien et al. (2004) is a mucin-degrading bacteria commonly found in the human gut. It represents about 3–5% of the humans’ microbiota. A. muciniphila is known for its probiotic properties and its potential benefits in the prevention and treatment of many metabolic disorders (Zhou, 2017). The abundance of A. muciniphila was strongly correlated with several parameters (glucose, insulin and leptin) which are the expression of metabolism either lipidic or glucidic and of inflammation (Schneeberger et al., 2015). The bacteria is involved in the modulation of the mucus thickness, gut barrier integrity and immunity, probably due to its localization in the mucus layer, close to the epithelial lays (Ottman et al., 2017; Zhou, 2017). Moreover, A. muciniphila plays an important role in the adaptation of the body to cold temperature. It acts as an energy sensor, its abundance increases with caloric deficiency and decreases with excess energy (Chevalier et al., 2015). Modulating the Microbiome —Probiotics hold great promise to modulation the microbiome and confer protection in conditions like metabolic endotoxemia (ME). It is clear that dysbiosis drives ME, thus, a healthy microbiome has the capability to protect the body from ME. The major issue with most probiotics is that they do not survive gastric passage to enter the small or large intestines intact and viable. However, there are spore probiotics that have the capacity to survive the harsh gastric passage and enter the intestines completely viable. As a result, bacterial spores are the only strains that have been shown to treat ME (McFarlin et al., 2017; Zhou, 2017).

The role of nutraceuticals on microbiota.

Figure 2: The role of nutraceuticals on microbiota.

Prebiotics are nutraceuticals which were approved for bolstering the growth of microbiota’s beneficial species. Carbohydrates are the main source of SCFAs—acetate, propionateand butyrate. Due to the action of SCFAs, the composition and diversity of microbiota can be changed in a positive way (Shashkova et al., 2016). The metabolites decrease the intestinal pH, suppress the intestinal pathogens’ growth and influence intestinal motility (Bron et al., 2017).

The term “prebiotic” refers to “dietary carbohydrates that stimulate the growth of gut bacteria or probiotics when these are administered externally.” A prebiotic is a non-digestible compound that through its metabolization by microorganisms in the gut modulates the composition and/or activity of the gut microbiota, thus conferring a beneficial physiological effect on the host” (Bindels et al., 2015). Fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), lactulose, non-digestible carbohydrates inulin, cellulose, resistant starches, hemicelluloses and pectins are the most used prebiotics in current medical practice (Dahiya et al., 2017; Espín, González-Sarrías & Tomás-Barberán, 2017). The bacterial abundance of gut microbiota is enhanced when a diet is low in prebiotics (Lucas López et al., 2017).

A prebiotic agent must fulfill certain criteria, such as not being hydrolyzed and absorbed in the first part of the gastrointestinal tract and is fermented by a limited number of beneficial bacteria in the colon (e.g., Lactobacillus) (Kolida, Tuohy & Gibson, 2002). Moreover, the prebiotic must be able to stimulate or metabolically activate the growth of these beneficial bacteria, in order to change the microflora into healthier one (Kolida, Tuohy & Gibson, 2002). The main effects of prebiotics include modulation of gut microbiota composition and production of energy metabolism, increasing mineral absorption, regulation of immune function and improvement of the intestinal barrier functions (Bron et al., 2017).

Soy beans and lactose from cow’s milk are the main sources of GOS. These are included especially in infant foods. The advantages of GOS are high solubility, neutral taste, stability at high temperature, acidity and low glycemic index. It was demonstrated that if the preterm infants were fed with a combination of 90% GOS and 10% FOS, the composition of gut microbiota increased in Bifidobacteria and Lactobacilli, resembling breast-fed infants’ microbiota (Sangwan et al., 2011). The mixture of GOS/FOS has a significant impact on increasing Bifidobacteria in the gut and on decreasing Clostridium but GOS alone has been reported to only increase Lactobacillus (Vandenplas, Zakharova & Dmitrieva, 2017).

A randomized, double-blind placebo-controlled study, which included 40 patients divided into two parallel groups (placebo vs prebiotic), demonstrated the beneficial effect of prebiotics (inulin and FOS) on the population of Lactobacillus and Bifidobacteria for oncologic patients who were treated with pelvic radiotherapy (RT). Stool samples were collected 7 days before the start of RT, 15 days after starting, at the end of RT and 3 weeks after RT was completed. The Lactobacillus and Bifidobacteria were analyzed and calprotectin level was determined as the marker of intestinal inflammation. The results showed that RT had a negative impact on Lactobacillus and Bifidobacteria in both groups, however, at 3 weeks after the end of RT, recovery of the gut microbiota was enhanced in patients treated with prebiotics (inulin and FOS) (Velasco et al., 2012). Therefore, inulin and FOS have a beneficial effect on Lactobacillus and Bifidobacteria populations of the gut.

Onions (Allium cepa) are a good source of carbohydrates, vitamins, and minerals. The health benefits of this plant are associated with its chemical components: carbohydrates (FOS and polysaccharides) with prebiotic effect, sulphur compounds (thiosulphinates) and phenolic compounds such as flavonoids (quercetin derivates) (Rodríguez Galdón, Rodríguez Rodríguez & Díaz Romero, 2008).

Filocamo et al. studied the effect of a commercial garlic powder upon pure, commensal bacterial cultures: Lactobacillus casei subsp casei DSMZ 20011, Clostridium nexile A2-232, Bifidobacterium longum DSMZ 20090 and Bacteroides ovatus. Results showed that C.  nexile and B. longum were more susceptible than L. casei and B. ovatum. C. nexile was the most sensitive strain, while L. casei was the least affected. Other studies demonstrated that garlic has bactericidal effect against E. coli, Salmonella typhimurium, Neisseria gonorrhoeae, Staphylococcus aureus and Enterococcus faecalis (Filocamo et al., 2012; Santhosha, Jamuna & Prabhavathi, 2013).

Aloe vera (Aloe barbadensis Miller) contains several compounds (anthraquinones, carbohydrates, vitamins, minerals, enzymes, amino acids) with many beneficial effects. Moreover, it is considered an important and natural source of prebiotics. It was observed that the leaf gel, due to oxidation, leads to fermentation and determines bacteria growth. Several research groups reported lactic acid bacteria after the fermentation of Aloe vera pulp, laying the grounds for studying the probiotic effect of Aloe vera. Five Lactobacillus brevis strains were isolated from naturally fermented Aloe vera pulp and the properties of a good probiotic were highlighted, such as high tolerance to acid (surviving 4 h in pH = 2.5) and the inhibition of the development of many enteropathogenic bacteria (C. jejuni, C. perfringens, S. aureus, Salmonella, E. coli) (Kim et al., 2014; Cuvas-Limón et al., 2016; Chiodelli et al., 2017).

Not only prebiotics and probiotics may influence gut microbiota. There are also other nutraceuticals, like phytoestrogens, polyphenols, etc. that may play a significant role in compounds that were isolated and characterized from them. The other nutraceuticals with benefic effect on gut microbiota are presented below.

Phytoestrogens are natural compounds with structural and functional similarities with estrogen hormones. These compounds are classified in: flavonoids, isoflavonoids, lignans, ellagitannins, coumestansand stilbenes (Bilal et al., 2014; Gaya et al., 2016). A single plant can contain many types of phytoestrogens and different parts of plants can contain different amounts of phytoestrogens (Jarošová et al., 2015). The main sources for phytoestrogens are fruits, vegetables and whole grains (Sirotkin & Harrath, 2014).

Flavonoids are transformed by bacterial species in the intestine, but they can also represent a substrate for the human gut microbiota. This can influence the absorption at intestinal level. Flavonoids influence and regulate the intestinal barrier and intestinal permeability and it was demonstrated that they have a direct trophic influence on Akkermansia and not on mucin production (Cassidy & Minihane, 2017).

Flavonoids possess antimicrobial effect, offering protection against pathogenic bacteria, fungi and viruses. In this era of antimicrobial resistance, the flavonoids could be considered suitable alternatives to antibiotics, especially in mild/moderate infections or in prevention (Iranshahi et al., 2015).

Anthocyanins belong to the flavonoids’ class and can be found in berries, grapes, apples etc. These compounds have an important role in the prophylaxis of many cardio vascular and neurological diseases, metabolic disorders and even cancer, especially due to their antioxidant properties (Chaiyasut et al., 2017). Berries are known for their high content in anthocyanins. The supplementation of mice’s diet with blueberrys or blackcurrants determined a significant change in gut microbiota, by promoting the anaerobic bacteria Bacteroidetes and Actinobacteria, probably through their antioxidant effect (Overall et al., 2017).

The isoflavonoids are a subclass of flavonoids, polyphenols, which is in high amount in soy, soy proteinand miso. The main sources of lignans are flaxseeds, soybeans, strawberries, carrots, cabbage, onion, garlicand cucumber (Blanck et al., 2003; Peterson et al., 2011).

The isoflavones are not active in primary form, as conjugate glucosides. The gut microbiota and intestinal mucosa have an important role in the conversion of these glucosides in compounds which are well absorbed and metabolized by the intestinal microflora into other metabolites (Vitale et al., 2013). These metabolites have estrogen-like activity (Laparra & Sanz, 2010). Isoflavonoids contain many glycosides, such as genistein, daidzein and glycitein. Daidzein is metabolized by gut bacteria to equol (Franke et al., 2014), which plays an important role in the health benefits of soy and it has strong estrogenic activity and antioxidant capacity. The main bacteria that contribute to the conversion of the isoflavonoids into equol inhabit the distal portion of the gut and belong to the family Coriobacteriaceae (Guadamuro et al., 2017).

Furthermore, along with isoflavonoids, ellagitannins and lignans are metabolized by gut bacteria into equol, urolithins and enterolignans, which have high bioavailability and estrogenic/antiestrogenic effects, antioxidant, anti-inflammatory and antiproliferative effects (Gaya et al., 2016).

Polyphenols have intensively been studied in the last years due to their beneficial effects in both cardio-vascular diseases and cancer. They are very expressed in our diet. The main sources of polyphenols are cocoa powder, dark chocolate, berries, beans, nuts, vegetables (red onion, spinach), soy, tea (black and green) and red wine (Manach et al., 2004).

There is a bidirectional relation between polyphenols and gut microbiota. The polyphenols’ bioavailability is increased by the microbiota, while unabsorbed polyphenols are involved in maintaining the equilibrium of microbiota in the gut. Suggested mechanisms imply protection against gastro-intestinal disorders and pathogens, strengthening intestinal epithelial tight cell junctions, increasing mucus secretion, stimulating cytokines and modulating the immune response (Ozdal et al., 2016).

From polyphenols class, quercetin is one of the most studied compounds in relationship with gut microbiota. It is a polyphenol derived from plants and belongs to flavonols, a subclass of flavonoid compounds. It can be found in apples, berries, grapes, onions, tea, tomatoes, seed and nuts, but also in medicinal botanicals like Hypericum perforatum, Ginkgo biloba and Sambucus Canadensis (Li et al., 2016).

It was demonstrated that quercetin has a modulatory role of gut microbiota when the overweight animals were fed with high-fat sucrose diet. Furthermore, quercetin ameliorates the Firmicutes/Bacteroidetes ratio in high-fat sucrose diet-fed rats, by increasing the titer of Bacteroides vulgatus and Akkermansia muciniphila, which have been inversely correlated to obesity. Moreover, it can decrease the titer of Eubacterium cylindroides and Bilophila wadsworthia, bacteria associated to diet-induced obesity (Etxeberria et al., 2015).

Also, tea, one of the most commonly consumed beverages, is manufactured from the young leaves of the Camellia sinensis plant. In today’s society, green or black tea is usually consumed (Cabrera, Giménez & López, 2003). These contain high concentrations of flavanols (epicatechin and catechin) and their esters. High levels of unabsorbed compounds of tea remain in the gut and play an important role in the intestine’s health. Caffeic acid, for example, inhibits the growth of many intestinal pathogenic bacteria, such as E. coli, Salmonella, Pseudomonas, Clostridium, Bacteroides (Lee et al., 2006). The main active compounds in green tea are polyphenols. They have important antioxidant and anti-inflammatory effects and influence the activity of NF-kB (nuclear factor kappa B), COX-2 (cyclooxygenase-2) and level of IL-2 (interleukin-2) (Oz, Chen & Villiers, 2013). On the other hand, black tea has several metabolites such as benzoic, phenylacetic and phenylpropionic acids with antimicrobial properties (Duynhoven et al., 2013).

Lactobacillus plantarum and Bacillus subtilis have a role in the metabolization of theaflavin in active compounds such as gallic acid, pyrogallol, mono gallate and gallate (Chen et al., 2012). There are studies which demonstrate that phenols and their derivates from tea inhibited the growth of pathogenic bacteria (Clostridium perfringens, Clostridium difficile or Bacteroides spp) while commensal bacteria (Lactobacillus, Bifidobacterium) were less affected. Therefore, phenolic compounds from tea modulate the gut bacteria and can act as a probiotic (Lee et al., 2006).

Resveratrol is a dietary polyphenol and as food supplement is mostly used by patients who suffer from cardiovascular diseases (Bonnefont-Rousselot, 2016; Imamura et al., 2017; Wahab et al., 2017). In an experimental study, it was demonstrated that resveratrol modulates the gut microbiota dysbiosis induced by high-fat diet. Thus, it stimulates the growing of Lactobacillus and Bifidobacterium, increases the Bacteroidetes/Firmicutes ratio and inhibits the growing of Enterococcus faecalis (Larrosa et al., 2009; Qiao et al., 2014).

Oregano vulgare is an aromatic plant with multiple phyto-therapeutic uses. Carvacrol and thymol are two main phenols from oregano and they have antimicrobial activity (e.g., on E. coli) (Fournomiti et al., 2015; Lopez-Romero et al., 2015). In an experimental study on pigs, it was demonstrated that oregano oil has protective effects against villous atrophy and epithelium cell necrosis and in the same time it decreases the seric endotoxin levels (Zou et al., 2016).

L-Glutamine (GLN) is a well-known amino acid which plays an important role in the gut and has an important contribution to generating energy. It is degraded by enterocytes and intestinal luminal bacteria and oxidized by the Krebs cycle, forming ATP (Wang et al., 2014).

In a double-blind study by De Souza et al. (2015) volunteers with body mass index (BMI) over 25 kg/m2 were enrolled and divided in two branches, one received GLN and the second one l-alanine (ALA). At the end of the study, there were 33 subjects, 21 in the branch treated with GLN and 12 in that with ALA. The gut microbiota was analyzed before and after 14- day treatment. The results showed that GLN determines changes in the composition of the gut microbiota and the ratio Firmicutes/Bacteroides decreased after GLN supplementation, mainly because Firmicutes were significantly reduced after GLN treatment. This ratio represents a good biomarker for obesity (De Souza et al., 2015).

In another study, Ren et al. (2014) used 100 mice, divided in two groups, in order to study the effects of dietary supplementation with 1 % L-glutamine for 14 days on the abundance of intestinal bacteria and the activation of intestinal innate immunity in mice. The first group was fed with a normal diet and the second one with normal diet supplemented with 1% GLN for 2 weeks. After this period, the animals were killed and the luminal contents in the jejunum and ileum were collected for analysis. Results showed that the effects of GLN on the abundance of intestinal bacteria were different among different parts of the intestine. Thus, Firmicutes were lower in GLN group than in control group in jejunum and ileum, but Bacteroidetes were comparable in both groups for these parts of the intestine. On the other hand, Streptococcus and Bifidobacterium had a high abundance in jejunum, while Lactobacillus was not affected. Streptococcus and Lactobacillus had comparable abundance in ileum in both investigated groups (GLN and control). The authors concluded that introduction of GLN in the mice’s diet changes the intestinal bacteria community and increases the intestinal immunity by affecting the NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells), MAPK (mitogen-activated protein kinase) and PI3K-Akt (phosphatidylinositol-3-kinases-Protein kinase B) signaling pathways (Ren et al., 2014).

Omega -3 and -6 fatty acids are the most used supplements in dyslipidemia, especially in hypertriglyceridemia.

Lui and coworkers studied the effect of omega fatty acids on changes induced in gut microbiota composition. For this purpose, 47 male mice were divided into three groups. Every group was fed with different types of diets rich in saturated fatty acids (SFAs), omega-3 polyunsaturated fatty acids (n −3 PUFAs) and omega-6 polyunsaturated fatty acids (n −6 PUFAs), respectively. The duration of the experiment was 14 weeks and the feces were collected at the beginning and at the end of the experiment. The observed effect on microbiota’s composition was represented by a significant decrease of Bacteroidetes/Firmicutes ratio in SFA-rich diet compared with the PUFA-rich diet. Thus, the mice fed with SFA-rich diet acquired a microbial profile similar to those of obese animals (Liu et al., 2012).

A study by Pusceddu and coworkers evaluated the role of n-3 PUFAs on the regulation of gut microbiota in early-life stress (maternal separation). Both non-separable (NS) and maternally separated (MS) groups were divided into three subgroups and every subgroup received saline, low doses of eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) (80% EPA, 20% DHA) (0.4g/Kg/day) and high doses of EPA/DHA (1g/Kg/day) respectively. The analysis of microbiota showed microbial dysbiosis in MS saline group, while a high dose of EPA/DHA was associated with a high level of Butyrivibrio (butyrate producing bacteria). Moreover, EPA/DHA restored the composition of the gut microbiota in MS rats regardless of the dose (Pusceddu et al., 2015).

Fish oil is one of the most used dietary supplements with a high content of n-3 PUFAs. Yu et al. evaluated in one of their studies whether this nutraceutical product (fish oil) has any effect on gut microbiota. The study used small animals (mice). These were divided into three groups: first received saline, the second received 5 mg/Kg fish oil and the third group 10 mg/Kg fish oil. The results demonstrated that fish oil inhibits the growth of Helicobacter, Clostridiales, Sphingomonadales, Firmicutes, Pseudomonas sp. and several uncultured bacteria. It is known that Helicobacter pylori plays an important role in the pathogenesis of ulcer, while Firmicutes are involved in obesity (Yu et al., 2014). Therefore, the importance of these results resides in the possibility of this supplement to become an important agent in the prophylaxis and treatment of ulcer disease and obesity.

Berberine, an alkaloid with quaternary ammonium structure, isolated from Rhizoma coptidis or Berberis sp., modulates the gut microbiota and has antimicrobial activity on Firmicutes and Bacteroidetes. Therefore, berberine may contribute to the increase of intestinal gene expression of Fiaf (fasting-induced adipose factor) in mice, which acts as a lipoprotein lipase inhibitor (Zhang et al., 2015; Xu et al., 2017).

For berberine, several important activities have been reported so far, e.g., cytostatic, antiproliferative and antioxidant properties. The alkaloid is considered an “antibiotic with broad spectrum” which may increase Bacteroides and decrease Ruminococcus in the terminal ileum and colon (Guo et al., 2016).

Table 2:
The influence of nutraceuticals on microbiota.
Nutraceuticals Changes in microbiota’s diversity Reference
Prebiotics Soy beans and lactose Bifidobacteria, Lactobacillus Sangwan et al. (2011)
Inulin and FOS Bifidobacteria, Lactobacillus Velasco et al. (2012)
Garlic Bifidobacterium longum , Clostridium nexile, E. coli, Salmonella typhimuriu, Neisseria gonorrhoeae, Staphylococcus aureus, Enterococcus faecalis Filocamo et al. (2012), Santhosha, Jamuna & Prabhavathi (2013)
Aloe vera C. jejuni, C. perfringens, S.aureus, Salmonella, E. coli Kim et al. (2014), Cuvas-Limón et al. (2016) and Chiodelli et al. (2017)
Phytoestrogens Flavonoids Akkermansia Cassidy & Minihane (2017)
Anthocyanins Bacteroidetes, Actinobacteria Overall et al. (2017)
Polyphenols Quercetin Bacteroides vulgatus, Akkermansia muciniphilaEubacterium cylindroides, Bilophila wadsworthia Etxeberria et al. (2015)
Tea from Camellia sinensis leaves E. coli, Salmonella, Pseudomonas, Clostridium, Bacteroides, Clostridium perfringens, Clostridium difficile Lee et al. (2006)
Resveratrol Lactobacillus,BifidobacteriumBacteroidetes/Firmicutes ratio ↓Enterococcus faecalis Larrosa et al. (2009), Qiao et al. (2014)
Amino acid L-Glutamine FirmicutesFirmicutes/Bacteroides ratio De Souza et al. (2015)
Fatty acids Omega -3 and -6 fatty acids Bacteroidetes/Firmicutes ratio ↓Helicobacter, Clostridiales, Sphingomonadales, Firmicutes, Pseudomonas sp. Liu et al. (2012), Yu et al. (2014)
Alkaloids Berberine Firmicutes, Bacteroidetes, Ruminococcus Zhang et al. (2015), Guo et al. (2016)
Algae Spirulina Staphulococcus aureus, Bacillus subtilis, E. coli, Pseudomonas aeruginosa Beheshtipour et al. (2013), Finamore et al. (2017)
Curcuminoids Curcumin LactobacillusCoriobacteriales Ramalingam et al. (2016).
DOI: 10.7717/peerj.4465/table-2

Spirulina (Arthrospira platensis), a cyanobacteria (blue–green algae), mostly used as a food supplement, has the capacity to inhibit the growth of Gram positive and Gram negative bacteria (Staphulococcus aureus, Bacillus subtilis, E. coli, Pseudomonas aeruginosa etc.). This antibacterial effect is due to an extracellular metabolite produced by spirulina. In addition, the microbiota’s modulatory effect of spirulina was attributed to the active compounds found in this plant (glutamate, aspartate, carbohydrates or phenolic compounds). These substances have a well-known antimicrobialand bacteriostatic effect and the capacity to stimulate the growth of probiotics (Beheshtipour et al., 2013; Finamore et al., 2017). Due to this effect, the spirulina biomass can become a natural product which could be added to fermented milk to increase the production of Lactobacillus and also the number of viable cells which reach the intestine (Bhowmik, Dubey & Mehra, 2009).

Curcumin is a bioactive component extracted from the Curcuma longa plant. In an experimental model of inflammatory bowel disease on small animals (mice) the supplementation of the diet with curcumin determined a significant change in gut microbiota: increasing the growth of Lactobacillus and decreasing the Coriobacteriales (Ramalingam et al., 2016).


This review attempted to underline the close link between microbiota and the most used nutraceuticals (Table 2). Thus, there are compounds, such as those mentioned above, which are nutraceuticals with real observed benefits on human health. In the past years, more and more patients have been using nutraceuticals without a medical recommendation, many of these being OTC (Over The Counter). Patients are not aware neither of the benefits nor of the risks of nutraceuticals, therefore the population could really benefit from a thorough education on this subject. Imbalance of microbiota is involved in many diseases, it can increase their risk of appearance, therefore it is critical to have a good knowledge of the main nutraceuticals in use and establish in what way they affect the composition of microbiota.

The changes in the gut microbiota are being accepted as important elements in the development of many diseases. Many nutraceuticals (prebiotics, probiotics, omega 3 acids, aloe vera etc.) may restore microbial homeostasis, reduce the negative effects of pathogenic agents, influence the inflammation pathway or increase the effect of standard allopathic therapy. Based on data published, it can be concluded that nutraceuticals mentioned above have promising clinical results and are likely to have a beneficial effect.

However, further studies are needed to complete the assessment of nutraceuticals in health’s benefit as a consequence of microbiota’s changing.

28 Citations   Views   Downloads